New Alzheimer’s Drug Receives FDA Approval
The drug is effective at removing an abnormal brain protein implicated in Alzheimer’s disease
You are trying to access subscriber-only content.
If you are a subscriber, .
If you are not a subscriber, or are only subscribed to the print edition, click here to subscribe now. Digital subscribers have unlimited access to our magazine articles and more!
The U.S. Food & Drug Administration (FDA) has approved a new drug to treat mild cognitive impairment (MCI, which has been defined as memory issues that may be a precursor for dementia) and early-stage Alzheimer’s disease (AD). The drug, donanemab (Kisunla®), is similar to lecanemab (Leqembi®), which was approved in July 2023. As with lecanemab, […]